PT  - JOURNAL ARTICLE
AU  - Bubar, Kate M.
AU  - Reinholt, Kyle
AU  - Kissler, Stephen M.
AU  - Lipsitch, Marc
AU  - Cobey, Sarah
AU  - Grad, Yonatan H.
AU  - Larremore, Daniel B.
TI  - Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
AID  - 10.1101/2020.09.08.20190629
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.08.20190629
4099  - http://medrxiv.org/content/early/2020/12/07/2020.09.08.20190629.short
4100  - http://medrxiv.org/content/early/2020/12/07/2020.09.08.20190629.full
AB  - Limited initial supply of SARS-CoV-2 vaccine raises the question of how to prioritize available doses. Here, we used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20-49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults over 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while partially addressing existing inequities in COVID-19 impact. While maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.Competing Interest StatementML discloses honoraria/consulting from Merck, Affinivax, Sanofi-Pasteur, and Antigen Discovery; research funding (institutional) from Pfizer, and an unpaid scientific advice to Janssen, Astra-Zeneca, and Covaxx (United Biomedical).Funding StatementThe work was supported in part by the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health. The work was supported in part by the Interdisciplinary Quantitative Biology (IQ Biology) PhD program at the BioFrontiers Institute, University of Colorado Boulder.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesContact matrices, demographic data and model parameters are available via the cited references in the manuscript.